Liquid Biopsy Evaluation and Repository Development at Princess Margaret

Last updated: August 19, 2024
Sponsor: University Health Network, Toronto
Overall Status: Active - Recruiting

Phase

N/A

Condition

Lymphoma

Lung Cancer

Melanoma

Treatment

N/A

Clinical Study ID

NCT03702309
LIBERATE
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The objective of this protocol is to develop an institution-wide liquid biopsy protocol that will establish a common process for collecting blood and corresponding archived tumor specimens for future research studies at the University Health Network's Princess Margaret Cancer Centre. Circulating cell-free nucleic acids (cfNA), including cell-free DNA (cfDNA) and cell-free RNA (cfRNA), are non-invasive, real-time biomarkers that can provide diagnostic and prognostic information before cancer diagnosis, during cancer treatment, and at disease progression. Cancer research scientists and clinicians at the Princess Margaret are interested in incorporating the collection of peripheral blood samples ("liquid biopsies") into research protocols as a means of non-invasively assessing tumor progression and response to treatment at multiple time points during a patient's course of disease.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Patients with either histological confirmation of a solid tumor or hematologicalmalignancy, OR patients identified as high-risk for cancer (based on identifiedaberration in cancer predisposition gene or on hormonal and/or family historywithout known aberration).

  2. Patient must be ≥ 18 years old.

  3. All patients must have signed and dated an informed consent form for this LIBERATEstudy.

  4. If patients are being co-consented for a separate primary research study listed inAppendix I, they must fulfill the eligibility criteria for that separate primaryresearch study. If there is a discrepancy in the eligibility criteria betweenprotocols, the separate primary research study's criteria take precedence.

Exclusion

Exclusion Criteria:

None

Study Design

Total Participants: 2500
Study Start date:
August 03, 2017
Estimated Completion Date:
July 06, 2025

Connect with a study center

  • Princess Margaret Cancer Centre

    Toronto, Ontario M5G2M9
    Canada

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.